Substituting with alternative iodinated contrast medium to prevent recurrent adverse drug reactions associated with its use: a meta-analysis

Abstract

ObjectivesTo systematically review and meta-analyze the recurrent rate of iodinated contrast medium (ICM)-associated adverse drug reactions (ADRs) and the preventive effect of using alternative ICM lacking a common carbamoyl side chain.Materials and methodsA systematic literature search was conducted in the MEDLINE and EMBASE databases to identify studies that investigated the recurrence rate of ICM-associated ADRs or hypersensitivity reactions (HSRs). Studies that included patients who subsequently underwent contrast-enhanced computed tomography scans after their index reactions were included, while studies with overlapping cohorts were excluded. The first search was conducted on November 10, 2023. The pooled recurrence rate of ICM-associated ADR was determined using the DerSimonian-Laird random-effects model. Subgroup analyses were also conducted based on the substitution of ICM, with particular consideration given to the N-(2,3-dihydroxypropyl) carbamoyl side chain.ResultsA total of ten original articles were included in the analysis, collectively spanning from June 2001 to March 2021. The pooled recurrence rate of ICM-associated ADR was not significantly different from that of ICM-associated HSR (16.6% [95% CI, 7.8-31.9%] vs. 15.5% [95% CI, 10.8-21.8%], p = 0.87). In the subgroup analyses, the pooled odds ratio for ICM-associated recurrent ADR when using a different ICM compared with using the same ICM was 0.31 (95% CI, 0.21-0.45), which means a 69% reduction. Moreover, the pooled odds ratio for ICM-associated recurrent ADR when substituting ICMs with different side chains compared with substituting with common side chains was 0.65 (95% CI, 0.52-0.82), which means an additional 35% reduction.ConclusionSubstituting with an alternative ICM led to a 69% reduction in recurrent ADRs, with an additional 35% reduction observed when using ICM lacking a common carbamoyl side chain.Key PointsQuestionNo standardized guidelines exist for replacing previously used iodinated contrast medium (ICM) to prevent recurrent adverse reactions.FindingsUsing alternative contrast medium with a different carbamoyl side chain prevents adverse drug reactions effectively.Clinical relevanceThis study advocates using alternative ICM without a common carbamoyl side chain to prevent recurrent adverse drug reactions in patients with a history of such events.Key PointsQuestionNo standardized guidelines exist for replacing previously used iodinated contrast medium (ICM) to prevent recurrent adverse reactions.FindingsUsing alternative contrast medium with a different carbamoyl side chain prevents adverse drug reactions effectively.Clinical relevanceThis study advocates using alternative ICM without a common carbamoyl side chain to prevent recurrent adverse drug reactions in patients with a history of such events.Key PointsQuestionNo standardized guidelines exist for replacing previously used iodinated contrast medium (ICM) to prevent recurrent adverse reactions.FindingsUsing alternative contrast medium with a different carbamoyl side chain prevents adverse drug reactions effectively.Clinical relevanceThis study advocates using alternative ICM without a common carbamoyl side chain to prevent recurrent adverse drug reactions in patients with a history of such events.